stock
RYTM · RHYTHM PHARMACEUTICALS, INC.
What RHYTHM PHARMACEUTICALS, INC. reports to the SEC, read from its filings.
Open in the appPrice
The live RYTM price and today's change.
Sign in to see thisChart
Thirty days of daily bars, with signal levels drawn on them.
Sign in to see thisSignals
The latest signal group Nakagai's scanner recorded on RYTM.
Sign in to see thisOptions positioning
Gamma exposure levels from the options market.
Sign in to see thisTechnicals
Trend, momentum and volatility gauges per timeframe.
Sign in to see thisWhat it is
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Filer (SEC EDGAR)
- EDGAR filing index
- Shares outstanding
- 68,852,082 as of 2026-08-01 (XBRL frame CY2026Q2I)
Key stats
Valuation
- P/E
- Locked
- P/S
- Locked
- P/B
- Locked
- Enterprise value
- Locked
- EV/EBIT
- Locked
- FCF yield
- Locked
Margins
- Gross
- —
- Operating
- -83.6%
- Net
- -3.8%
Returns
- ROE
- -8.7%
- ROA
- -2.1%
Health
- Current ratio
- 3.5x
- Debt/equity
- 1.0x
Deep value
- NCAV
- $206.60M
- NCAV per share
- $3.00
- Price/NCAV
- Locked
- NNWC
- -$108.79M
- NNWC per share
- -$1.58
- Price/NNWC
- Locked
Valuation and the price multiples are built on the live price. Trailing twelve months to 2026-06-30; balance sheet at 2026-06-30.
Sign in to see thisDebt is long-term debt and its current portion. Commercial paper and short-term borrowings are not counted.
Results
| Period end | Revenue | Gross profit (not reported by this company) | Operating income | Net income | Filing |
|---|---|---|---|---|---|
| 2026-06-30 | $71.25M | —Gross profit: unreported by this company. | -$48.55M | -$49.30M | 10-Q filed 2026-08-04 |
| 2026-03-31 | $60.11M | —Gross profit: unreported by this company. | -$52.36M | -$55.64M | 10-Q filed 2026-08-04 Assembled from more than one filing; the filing above is only the newest of them. |
| 2025-12-31 | $57.25M | —Gross profit: unreported by this company. | -$47.06M | $148.84M | DEF 14A filed 2026-04-29 Derived: the full year minus the first three quarters, not a figure this filer reported as a quarter. Assembled from more than one filing; the filing above is only the newest of them. |
| 2025-09-30 | $51.30M | —Gross profit: unreported by this company. | -$52.65M | -$52.90M | 10-Q filed 2025-11-04 |
| 2025-06-30 | $48.50M | —Gross profit: unreported by this company. | -$45.30M | -$46.63M | 10-Q filed 2026-08-04 |
| 2025-03-31 | $32.70M | —Gross profit: unreported by this company. | -$47.00M | -$49.50M | 10-Q filed 2026-08-04 Assembled from more than one filing; the filing above is only the newest of them. |
| 2024-12-31 | $41.83M | —Gross profit: unreported by this company. | -$41.25M | $217.01M | DEF 14A filed 2026-04-29 Derived: the full year minus the first three quarters, not a figure this filer reported as a quarter. Assembled from more than one filing; the filing above is only the newest of them. |
| 2024-09-30 | $33.25M | —Gross profit: unreported by this company. | -$43.88M | -$43.64M | 10-Q filed 2025-11-04 |
- Assets
- $437.27M
- Equity
- $102.98M
Balance as of 2026-06-30.
Ten years
| Fiscal year end | Revenue | Operating income | Net income | Free cash flow |
|---|---|---|---|---|
| 2025-12-31 | $189.76M | -$192.02M | -$196,539 | -$116.63M |
| 2024-12-31 | $130.13M | -$265.50M | -$260,602 | -$113.88M |
| 2023-12-31 | $77.43M | -$184.36M | -$184,678 | -$136.20M |
| 2022-12-31 | $23.64M | -$179.16M | -$181,119 | -$173.71M |
| 2021-12-31 | $3.15M | -$170.06M | -$69,612 | -$146.44M |
| 2020-12-31 | $0 | -$136.57M | -$134.00M | -$122.19M |
| 2019-12-31 | $0 | -$146.00M | -$140.73M | -$126.14M |
| 2018-12-31 | $0 | -$78.42M | -$74.06M | -$62.78M |
| 2017-12-31 | $0 | -$32.41M | -$33.71M | -$29.59M |
| 2016-12-31 | $0 | -$25.91M | -$25.87M | -$24.28M |
Company filings
since Thu Feb 26
events
Results, Regulation FD disclosure, Other event
ResultsRegulation FD disclosureOther eventAug 48-KShareholder vote results
Shareholder vote resultsJun 258-KRegulation FD disclosure, Other event
Regulation FD disclosureOther eventJun 158-KResults
ResultsMay 58-KExecutive or director change, Regulation FD disclosure
Executive or director changeRegulation FD disclosureApr 38-KRegulation FD disclosure, Other event
Regulation FD disclosureOther eventMar 268-K
5% owners ()
Perceptive Advisors LLC
Stake update
Vanguard Capital Management
Passive stake
The Vanguard Group
Stake update
RA Capital Management, L.P.
Stake update
PRIMECAP MANAGEMENT CO/CA/
Stake update
Insiders, politicians and funds
Insider trades, last 90 days
Meeker David P
President and CEO, Director
Sale$5,133,442Sep 14, 7:37 PM ET
Smith Hunter C
Chief Financial Officer
Sale$6,619,913Sep 1, 4:22 PM ET
Shulman Joseph
Chief Technical Officer
Sale$608,210Aug 17, 6:00 PM ET
Garfield Alastair
Chief Scientific Officer
Sale$912,703Aug 17, 5:57 PM ET
Lee Jennifer Kayden
EVP, Head of North America
Sale$8,901,531Aug 14, 7:04 PM ET
Politician trades, last 90 days
No politician trades filed in the last 90 days.
Funds
- Duquesne Family Office
Period Tue 30 Jun 2026
0.4%New - Point72
Period Tue 30 Jun 2026
0.1%Trimmed
News
Stories that named RYTM, and the market events around them.
Sign in to see thisBoard
Recent signals
Signals open up here once a member has posted about RYTM.
Signals are informational.
Posts · 0
No posts yet.
nakagai
Signals on RYTM come from a rule, not a model.
Nakagai’s scanner records a signal the moment a strategy’s rule matches on the bars. Members read those signals on their own desk, where an agent journals the tape and briefs them in plain English.
Members post on the RYTM board